88 related articles for article (PubMed ID: 19073527)
1. Novel antibody approaches for T-cell lymphomas.
Goodman OB; Dang NH
Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S193-8. PubMed ID: 19073527
[TBL] [Abstract][Full Text] [Related]
2. Receptor-directed therapy of T-cell leukemias and lymphomas.
Morris JC; Waldmann TA; Janik JE
J Immunotoxicol; 2008 Apr; 5(2):235-48. PubMed ID: 18569395
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Dunleavy K; Wilson WH
Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
[No Abstract] [Full Text] [Related]
4. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab in CLL and other lymphoid neoplasms.
Ravandi F; O'brien S
Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
[TBL] [Abstract][Full Text] [Related]
6. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
8. Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
Klemke CD; Goerdt S
G Ital Dermatol Venereol; 2008 Dec; 143(6):365-74. PubMed ID: 19169209
[TBL] [Abstract][Full Text] [Related]
9. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma.
Wulf GG; Hasenkamp J; Jung W; Chapuy B; Truemper L; Glass B
Bone Marrow Transplant; 2005 Aug; 36(3):271-3. PubMed ID: 15937499
[No Abstract] [Full Text] [Related]
10. Alemtuzumab.
Ravandi F; O'Brien S
Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
12. Emerging monoclonal antibody therapies for multiple sclerosis.
Cree B
Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.
Weissenbacher A; Boesmueller C; Brandacher G; Oellinger R; Pratschke J; Schneeberger S
Immunotherapy; 2010 Nov; 2(6):783-90. PubMed ID: 21091110
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab (Compath) off-label for relapsing multiple sclerosis.
Med Lett Drugs Ther; 2009 Mar; 51(1307):17-8. PubMed ID: 19265776
[No Abstract] [Full Text] [Related]
15. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
16. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
[TBL] [Abstract][Full Text] [Related]
18. [Immune mechanisms and novel therapeutic targets for ITP].
Kuwana M; Ikeda Y
Rinsho Ketsueki; 2005 Feb; 46(2):99-103. PubMed ID: 16447702
[No Abstract] [Full Text] [Related]
19. Current status of antibody therapy in ALL.
Ai J; Advani A
Br J Haematol; 2015 Feb; 168(4):471-80. PubMed ID: 25382151
[TBL] [Abstract][Full Text] [Related]
20. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]